These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 31200846)

  • 21. Comparison of PSA density and lesion volume strategies for selecting men with equivocal PI-RADS 3 lesions on bpMRI for biopsies.
    Kortenbach KC; Løgager V; Thomsen HS; Boesen L
    Abdom Radiol (NY); 2023 Feb; 48(2):688-693. PubMed ID: 36318331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of Biparametric Magnetic Resonance Imaging Combined With Prostate Specific Antigen Density in Pre-biopsy Detection of Clinically Insignificant Prostate Cancer.
    Sekito S; Terabe T; Shibahara T; Onishi T
    Anticancer Res; 2021 Apr; 41(4):2183-2186. PubMed ID: 33813431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials).
    Perez IM; Jambor I; Kauko T; Verho J; Ettala O; Falagario U; Merisaari H; Kiviniemi A; Taimen P; Syvänen KT; Knaapila J; Seppänen M; Rannikko A; Riikonen J; Kallajoki M; Mirtti T; Lamminen T; Saunavaara J; Pahikkala T; Boström PJ; Aronen HJ
    J Magn Reson Imaging; 2020 May; 51(5):1556-1567. PubMed ID: 31750988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population.
    Fascelli M; Rais-Bahrami S; Sankineni S; Brown AM; George AK; Ho R; Frye T; Kilchevsky A; Chelluri R; Abboud S; Siddiqui MM; Merino MJ; Wood BJ; Choyke PL; Pinto PA; Turkbey B
    Urology; 2016 Feb; 88():125-34. PubMed ID: 26680244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
    Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
    Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
    Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
    Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance.
    Radtke JP; Boxler S; Kuru TH; Wolf MB; Alt CD; Popeneciu IV; Steinemann S; Huettenbrink C; Bergstraesser-Gasch C; Klein T; Kesch C; Roethke M; Becker N; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):288-96. PubMed ID: 26078202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
    Guo S; Zhang J; Wang Y; Jiao J; Li Z; Cui C; Chen J; Yang W; Ma S; Wu P; Jing Y; Wen W; Kang F; Wang J; Qin W
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):288-293. PubMed ID: 38160227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are targeted prostate biopsies ready to replace systematic prostate biopsies?
    Celma A; López R; Roche S; Planas J; Regis L; Placer J; Borque A; Esteban LM; de Torres I; Morote J
    Actas Urol Esp (Engl Ed); 2019 Dec; 43(10):573-578. PubMed ID: 31679807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
    Schouten MG; van der Leest M; Pokorny M; Hoogenboom M; Barentsz JO; Thompson LC; Fütterer JJ
    Eur Urol; 2017 Jun; 71(6):896-903. PubMed ID: 28063613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
    Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
    Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study.
    Falagario U; Jambor I; Taimen P; Syvänen KT; Kähkönen E; Merisaari H; Montoya Perez I; Knaapila J; Steiner A; Verho J; Tewari A; Aronen HJ; Carrieri G; Boström PJ; Ettala O
    World J Urol; 2021 Jun; 39(6):1879-1887. PubMed ID: 32778912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
    Kim MJ; Park SY
    J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
    Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
    Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
    Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.